ACON · Aclarion, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.1K | - | $18.9K | $19.3K | $19.0K | - | $14.4K | $11.0K | $10.1K | - |
| Cost of Revenue | $17.4K | - | $14.6K | $14.2K | $23.5K | - | $21.3K | $23.3K | $19.5K | - |
| Gross Profit | $3.8K | - | $4.4K | $5.1K | ($4.5K) | - | ($6.9K) | ($12.3K) | ($9.4K) | - |
| R&D | $315.4K | - | $302.0K | $270.4K | $198.2K | - | $195.8K | $202.1K | $239.0K | - |
| SG&A | $1.77M | - | $900.9K | $1.13M | $986.7K | - | $860.5K | $696.1K | $845.8K | - |
| Total Operating Expenses | $2.99M | - | $1.84M | $1.74M | $1.49M | - | $1.29M | $1.12M | $1.27M | - |
| D&A | $60.9K | - | - | - | $55.2K | - | - | - | $45.1K | - |
| Operating Income | ($2.99M) | - | ($1.83M) | ($1.74M) | ($1.49M) | - | ($1.30M) | ($1.14M) | ($1.28M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | $335.8K | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($2.85M) | - | ($1.71M) | ($1.60M) | ($2.04M) | - | ($1.37M) | ($1.24M) | ($2.40M) | - |
| EPS - Basic | ($1.34) | - | ($2.93) | ($2.75) | ($9.32) | - | ($1356.75) | ($1356.75) | ($3979.80) | - |
| EPS - Diluted | ($1.34) | - | ($2.93) | ($2.75) | ($9.32) | - | ($1356.75) | ($1356.75) | ($3979.80) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19.00M | $12.02M | $11.34M | $12.83M | $14.75M | $453.7K | $1.31M | $1.17M | $2.13M | $1.02M |
| Accounts Receivable | $40.6K | $29.7K | $32.0K | $20.9K | $19.2K | $18.3K | $17.0K | $19.7K | $17.2K | $13.3K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $587.3K | $333.0K | $274.4K | $281.5K | $516.3K | $531.6K | $331.8K | $179.1K | $195.7K | $760.5K |
| Current Assets | $19.38M | $12.40M | $11.90M | $13.44M | $15.16M | $824.3K | $1.90M | $1.85M | $2.54M | $1.29M |
| Total Assets | $20.64M | $13.67M | $13.20M | $14.75M | $16.48M | $2.12M | $3.19M | $3.09M | $3.73M | $2.46M |
| Current Liabilities | $986.2K | $837.3K | $699.7K | $564.4K | $699.0K | $1.15M | $678.3K | $1.45M | $1.22M | $3.19M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $986.2K | $837.3K | $699.7K | $564.4K | $1.15M | - | $678.3K | $1.45M | $3.19M | - |
| Stockholders' Equity | $19.65M | $12.84M | $12.50M | $14.19M | $15.78M | $970.1K | $2.51M | $1.64M | $2.51M | ($728.0K) |
| Retained Earnings | ($61.35M) | ($58.50M) | ($56.61M) | ($54.90M) | ($53.30M) | ($51.26M) | ($49.27M) | ($47.92M) | ($46.68M) | ($44.28M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.64M) | - | - | - | ($2.51M) | - | - | - | ($2.24M) | - |
| Investing Cash Flow | ($49.3K) | - | - | - | ($78.3K) | - | - | - | ($63.7K) | - |
| Financing Cash Flow | $9.68M | - | - | - | $16.89M | - | - | - | $3.41M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 17.7% | - | 23.2% | 26.6% | -23.6% | - | -48.1% | -112.3% | -92.6% | - |
| Operating margin | -14129.3% | - | -9666.2% | -8988.6% | -7856.0% | - | -8995.3% | -10350.6% | -12609.3% | - |
| EBITDA margin | -13841.2% | - | - | - | -7565.5% | - | - | - | -12163.3% | - |
| Net margin | -13498.5% | - | -9008.0% | -8285.9% | -10728.4% | - | -9482.7% | -11285.0% | -23720.6% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 1492.0% | - | 1594.5% | 1399.8% | 1043.6% | - | 1359.0% | 1842.1% | 2363.5% | - |
| SG&A / Revenue | 8356.1% | - | 4756.1% | 5836.0% | 5195.4% | - | 5972.5% | 6344.9% | 8363.1% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -13.8% | - | -12.9% | -10.8% | -12.4% | - | -42.9% | -40.1% | -64.4% | - |
| Return on equity | -14.5% | - | -13.6% | -11.3% | -12.9% | - | -54.4% | -75.4% | -95.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 19.65 | 14.81 | 17.01 | 23.81 | 21.68 | 0.71 | 2.80 | 1.28 | 2.08 | 0.40 |
| Quick ratio | 19.65 | 14.81 | 17.01 | 23.81 | 21.68 | 0.71 | 2.80 | 1.28 | 2.08 | 0.40 |
| Cash ratio | 19.27 | 14.35 | 16.21 | 22.72 | 21.10 | 0.39 | 1.93 | 0.81 | 1.75 | 0.32 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | -3.8x | - |
| Equity multiplier | 1.05 | 1.07 | 1.06 | 1.04 | 1.04 | 2.19 | 1.27 | 1.88 | 1.49 | -3.38 |
| Liabilities / Assets | 0.05 | 0.06 | 0.05 | 0.04 | 0.07 | - | 0.21 | 0.47 | 0.86 | - |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 701d | - | 617d | 395d | 368d | - | 429d | 656d | 621d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | 12327d | - | 6880d | 7247d | 8026d | - | 5677d | 2807d | 3668d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.4x | - | 0.3x | 0.3x | 0.2x | - | 6224.4x | 12944.0x | 6484.0x | - |
| P / S | 329.5x | - | 230.6x | 226.8x | 124.8x | - | 1084326.7x | 1937505.6x | 1606230.9x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 11.3% | - | 31.5% | 76.1% | 87.8% | - | -24.4% | -35.7% | -60.3% | - |
| Revenue CAGR (3y) | -6.0% | - | 20.4% | 21.9% | 28.1% | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | 52.1% | - | -1304.7% | -452.8% | - | - |
| Operating income growth (YoY) | -100.2% | - | -41.3% | -52.9% | -17.0% | - | -11.5% | 19.2% | -8.0% | - |
| Net income growth (YoY) | -40.1% | - | -24.9% | -29.3% | 15.1% | - | -36.9% | 15.5% | -102.7% | - |
| EPS growth (YoY) | 85.6% | - | 99.8% | 99.8% | 99.8% | - | -1130525.0% | -288570.2% | -2653100.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 24.5% | 1223.1% | 398.1% | 764.1% | 529.9% | - | - | 15963.6% | 122.7% | - |
Peer comparison
Same SIC group: Services-Medical Laboratories
Comparing Aclarion against the 5 most active filers in the same SIC group.